secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001171843-25-004810
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Anika Therapeutics Q2 2025 revenue down 8%; Hyalofast trial misses co-primary endpoints
--------------------------------------------------------------------------------

- Q2 2025 revenue $28.2M, down 8% YoY; Commercial Channel flat, OEM Channel down 13%
- Regenerative Solutions revenue rose 41% driven by Integrity implant outperformance (full-year 2024 surpassed in H1 2025)
- Hyalofast Phase III trial missed co-primary endpoints but showed statistically significant improvements in secondary endpoints; final PMA module on track for H2 2025
- Company reaffirms 2025 revenue/EBITDA guidance but revises long-term outlook for Hyalofast launch potential delay to 2027
- Operating expenses down 17% YoY; production yield issues resolved in June 2025 with no patient impact

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184325004810/0001171843-25-004810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184325004810/f8k_073025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer